Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing
Swiss tech-bio firm Atlas Bio launched from stealth with a $10 million seed round led by Creandum and a previously unannounced $2.5 million pre-seed round, totaling $12.5 million. The company is building an AI foundation model trained on roughly 2 million RNA readouts from human tissue to simulate patient-level efficacy and safety in virtual clinical trials. This approach targets Phase II trials, which typically cost over $100 million and take two to three years, with approximately 70 percent of drugs failing at this stage.
Key points
- Total funding of $12.5M across seed and pre-seed rounds
- AI model trained on 2 million human tissue RNA readouts
- Aims to replace expensive Phase II trials and animal testing
- Phase II currently costs $100M+ with 70% failure rate
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. Tech.eu did the reporting; read the original for the full story.
Read the full story at Tech.eu
